Sanofi India announced that Rachid Ayari will step down from his positions as Whole Time Director, Chief Financial Officer (CFO), and Key Managerial Personnel (KMP) of the company, effective from the close of business hours on September 30, 2026. According to the latest regulatory filing, Ayari informed the board of his decision through a letter dated July 22, 2026, and has decided to relinquish his current responsibilities following his transition to another role within the Sanofi group. Following his cessation, Ayari will no longer serve as Whole Time Director, CFO, KMP, Senior Management Personnel, or a member of the Risk Management Committee of the company.
As reported by Business Standard, Sanofi India expressed its appreciation for Ayari's contributions, expert guidance, and support during his tenure with the company. The company is currently in the process of identifying a suitable candidate for the position of Chief Financial Officer, who will also be appointed as a Key Managerial Personnel. The company will make an announcement regarding the appointment in due course.
According to the latest regulatory filing, Rachid Ayari joined Sanofi in 2017 as the CFO in Algeria before moving to the same position in Russia and the Central Asia region (EURASIA). He was subsequently appointed as the CFO for Sanofi India in December 2023. Prior to joining Sanofi, Ayari worked in Pfizer as Finance Director in the North African region, bringing extensive international pharmaceutical experience to his role at Sanofi India.
According to Business Standard, Sanofi India is engaged in the manufacture and marketing of pharmaceutical products and vaccines. On a standalone basis, Sanofi India's net profit declined 14.14% to ₹102.60 crore while net sales declined 11.87% to ₹472.30 crore in Q4 March 2026 over Q4 March 2025. The scrip shed 0.33% to ₹3,392.40 on the BSE.
